45. Eosinophilic granulomatosis with Polyangiitis
[
26 clinical trials,
32 drugs（DrugBank:
20 drugs),
18 target genes / 93 target pathways ]
Searched query = "Eosinophilic granulomatosis with Polyangiitis", "EGPA", "Eosinophilic multiple vasculitis granulomatous disease", "Allergic granulomatous angiitis", "Churg Strauss syndrome"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04157348 | October 29, 2019 | 11 November 2019 | A Study to Evaluate if Benralizumab Compared to Mepolizumab May be Beneficial in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) | A Randomized, Double-blind, Active-controlled 52-week Study With an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab Compared to Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) in Patients Receiving Standard of Care Therapy | Eosinophilic Granulomatous Vasculitis | Biological: Benralizumab;Biological: Mepolizumab;Biological: Placebo to Mepolizumab;Biological: Placebo to Benralizumab | AstraZeneca | Recruiting | 18 Years | 130 Years | All | 140 | Phase 3 | United States;Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom | |
| 2 | NCT03482479 | February 4, 2019 | 22 October 2019 | Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis | Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis | Eosinophilic Granulomatosis With Polyangiitis (EGPA);Churg-Strauss Syndrome (CSS);Giant Cell Arteritis;Granulomatosis With Polyangiitis;Microscopic Polyangiitis;Polyarteritis Nodosa;Takayasu Arteritis | Drug: Naltrexone Hydrochloride;Other: Placebo Comparator | University of Pennsylvania | Recruiting | 18 Years | N/A | All | 60 | Phase 2 | United States | |
| 3 | NCT03557060 | June 25, 2018 | 17 September 2018 | NUCALA® Special Drug Use Investigation (EGPA, Long-term) | NUCALA ® Subcutaneous Injection Special Drug Use Investigation (EGPA, Long-term) | Churg-Strauss Syndrome | Drug: Nucala | GlaxoSmithKline | Not recruiting | N/A | N/A | All | 300 | Phase 1 | Japan | |
| 4 | NCT03164473 | March 7, 2018 | 25 February 2019 | Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. | MAINtenance of Remission With RITuximab Versus Azathioprine for Patients With Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. A Prospective, Randomized, Controlled, Double-blind Study: the MAINRITSEG Trial | Eosinophilic Granulomatosis With Polyangiitis | Drug: Rituximab;Drug: Azathioprine;Drug: Placebo-rituximab;Drug: Placebo-azathioprine | Assistance Publique - Hôpitaux de Paris | French Vasculitis Study Group | Recruiting | 18 Years | N/A | All | 98 | Phase 4 | France |
| 5 | NCT02947945 | September 12, 2017 | 16 December 2017 | Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study | Open-Label, to Evaluate the Efficacy and Safety of Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study: RITE Study | Asthma | Drug: Reslizumab | National Jewish Health | TEVA | Recruiting | 18 Years | N/A | All | 10 | Phase 2 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT03010436 | April 15, 2017 | 16 December 2017 | Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study | The Efficacy and Safety of Benralizumab In the Treatment of Eosinophilic Grandulomatosis With Polyangiitis (EGPA) Study: BITE | Asthma | Drug: Benralizumab | National Jewish Health | AstraZeneca | Recruiting | 18 Years | 100 Years | All | 10 | Phase 2 | United States |
| 7 | NCT02807103 | December 5, 2016 | 8 April 2019 | Rituximab in Eosinophilic Granulomatosis With Polyangiitis | Evaluation of Rituximab-based Regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Newly-Diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. Prospective, Randomized, Controlled, Double-blind Study | Eosinophilic Granulomatosis With Polyangiitis (EGPA) | Drug: Rituximab;Drug: Placebo-rituximab;Drug: Cyclophosphamide;Drug: Placebo-cyclophosphamide | Assistance Publique - Hôpitaux de Paris | French Vasculitis Study Group (FVSG) | Recruiting | 18 Years | N/A | All | 108 | Phase 3 | France |
| 8 | NCT02728271 | April 2016 | 16 December 2017 | Immuno-ablation With Chemoimmunoradiation and Autologous Stem Cell Transplant for Churg-Strauss Syndrome | A Pilot Study of Immuno-ablation With Chemoimmunoradiation Followed by Autologous Hematopoietic Progenitor Cell (HPC) Transplant for Adult Subjects With Churg-Strauss Syndrome | Churg-Strauss Syndrome | Biological: HPC cell infusion | Mounzer Agha | Not recruiting | 18 Years | 60 Years | All | 1 | Early Phase 1 | ||
| 9 | EUCTR2016-000275-25-FR | 21/03/2016 | 18 April 2016 | Evaluation of Rituximab-based Regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Newly-Diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. Prospective, randomized, controlled, double-blind study. - REOVAS | Evaluation of Rituximab-based Regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Newly-Diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. Prospective, randomized, controlled, double-blind study. - REOVAS | Patients with a diagnosis of EGPA with newly-diagnosed disease or with a relapsing disease at the time of screening MedDRA version: 19.0 Level: PT Classification code 10048594 Term: Allergic granulomatous angiitis System Organ Class: 10021428 - Immune system disorders | Trade Name: RITUXIMAB Product Name: RITUXIMAB Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB Other descriptive name: RITUXIMAB Concentration unit: g gram(s) Concentration type: equal Concentration number: 10mg/ml- Pharmaceutical form of the placebo: Concentrate for solution for injection Route of administration of the placebo: Intravenous use Trade Name: CYCLOPHOSPHAMIDE Product Name: CYCLOPHOSPHAMIDE Pharmaceutical Form: Powder and solvent for solution for infusion INN or Proposed INN: CYCLOPHOSPHAMIDE Concentration unit: mg/m2 milligram(s)/square meter Concentration type: equal Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use Trade Name: MESNA Product Name: MESNA Pharmaceutical Form: Solution for injection INN or Proposed INN: mesna Other descriptive name: MESNA Concentration unit: mg/m2 milligram(s)/square meter Concentration type: equal Concentration number: 100mg/ml- Pharmaceutical form of the placebo: Concentrate for solution for injection Route of administration of the placebo: Intravenous use | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | Authorised | Female: yes Male: yes | France | |||||
| 10 | EUCTR2014-003162-25-BE | 06/07/2015 | 28 February 2019 | Mepolizumab Long-term Access Programme for Subjects who Participated in Study MEA115921 | Mepolizumab Long-term Access Programme for Subjects who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard-of-care Therapy) | Eosinophilic Granulomatosis with Polyangiitis (formerly known as Churg-Strauss Syndrome) MedDRA version: 20.0 Level: LLT Classification code 10018701 Term: Granulomatous disease System Organ Class: 100000004867 MedDRA version: 20.0 Level: LLT Classification code 10014956 Term: Eosinophilic granuloma System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10072580 Term: Granulomatous polyangiitis System Organ Class: 100000004866 MedDRA version: 20.1 Level: LLT Classification code 10014957 Term: Eosinophilic granulomatous vasculitis System Organ Class: 100000004870 MedDRA version: 20.0 Level: LLT Classification code 10056218 Term: Necrotising granulomatous vasculitis System Organ Class: 100000004866 MedDRA version: 20.0 Level: LLT Classification code 10068462 Term: Eosinophilic asthma System Organ Class: 100000004855 MedDRA version: 20.0 Level: LLT Classification code 10036023 Term: Polyangiitis System Organ Class: 100000004866 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: SB-240563 (mepolizumab) Product Code: SB-240563 (mepolizumab) Pharmaceutical Form: Injection INN or Proposed INN: Mepolizumab CAS Number: 196078-29-2 Current Sponsor code: SB-240563 Other descriptive name: MEPOLIZUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- | GlaxoSmithKline Research Ltd | Authorised | Female: yes Male: yes | 115 | Phase 3 | United States;Canada;Belgium;Germany;United Kingdom;Japan | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT03298061 | March 21, 2015 | 7 October 2019 | Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921 | Mepolizumab Long-term Access Programme for Subjects Who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis in Subjects Receiving Standard-of-care Therapy) | Churg-Strauss Syndrome | Drug: Mepolizumab;Drug: Prednisolone | GlaxoSmithKline | Not recruiting | 18 Years | N/A | All | 104 | Phase 3 | United States;Belgium;Canada;France;Germany;Japan;United Kingdom | |
| 12 | EUCTR2014-003162-25-GB | 19/03/2015 | 28 February 2019 | Mepolizumab Long-term Access Programme for Subjects who Participated in Study MEA115921 | Mepolizumab Long-term Access Programme for Subjects who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard-of-care Therapy) | Eosinophilic Granulomatosis with Polyangiitis (formerly known as Churg-Strauss Syndrome) MedDRA version: 20.0 Level: LLT Classification code 10018701 Term: Granulomatous disease System Organ Class: 100000004867 MedDRA version: 20.0 Level: LLT Classification code 10014956 Term: Eosinophilic granuloma System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10072580 Term: Granulomatous polyangiitis System Organ Class: 100000004866 MedDRA version: 20.1 Level: LLT Classification code 10014957 Term: Eosinophilic granulomatous vasculitis System Organ Class: 100000004870 MedDRA version: 20.0 Level: LLT Classification code 10056218 Term: Necrotising granulomatous vasculitis System Organ Class: 100000004866 MedDRA version: 20.0 Level: LLT Classification code 10068462 Term: Eosinophilic asthma System Organ Class: 100000004855 MedDRA version: 20.0 Level: LLT Classification code 10036023 Term: Polyangiitis System Organ Class: 100000004866 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: SB-240563 (mepolizumab) Product Code: SB-240563 (mepolizumab) Pharmaceutical Form: Injection INN or Proposed INN: Mepolizumab CAS Number: 196078-29-2 Current Sponsor code: SB-240563 Other descriptive name: MEPOLIZUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- | GlaxoSmithKline Research Ltd | Authorised | Female: yes Male: yes | 42 | Phase 3 | France;Canada;Belgium;Germany;Japan;United Kingdom | |||
| 13 | EUCTR2014-003162-25-DE | 26/02/2015 | 28 February 2019 | Mepolizumab Long-term Access Programme for Subjects who Participated in Study MEA115921 | Mepolizumab Long-term Access Programme for Subjects who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard-of-care Therapy) | Eosinophilic Granulomatosis with Polyangiitis (formerly known as Churg-Strauss Syndrome) MedDRA version: 20.0 Level: LLT Classification code 10018701 Term: Granulomatous disease System Organ Class: 100000004867 MedDRA version: 20.0 Level: LLT Classification code 10072580 Term: Granulomatous polyangiitis System Organ Class: 100000004866 MedDRA version: 20.0 Level: LLT Classification code 10014956 Term: Eosinophilic granuloma System Organ Class: 100000004864 MedDRA version: 20.1 Level: LLT Classification code 10014957 Term: Eosinophilic granulomatous vasculitis System Organ Class: 100000004870 MedDRA version: 20.0 Level: LLT Classification code 10056218 Term: Necrotising granulomatous vasculitis System Organ Class: 100000004866 MedDRA version: 20.0 Level: LLT Classification code 10068462 Term: Eosinophilic asthma System Organ Class: 100000004855 MedDRA version: 20.0 Level: LLT Classification code 10036023 Term: Polyangiitis System Organ Class: 100000004866 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: SB-240563 (mepolizumab) Product Code: SB-240563 (mepolizumab) Pharmaceutical Form: Lyophilisate for solution for injection INN or Proposed INN: Mepolizumab CAS Number: 196078-29-2 Current Sponsor code: SB-240563 Other descriptive name: MEPOLIZUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- | GlaxoSmithKline Research Ltd | Authorised | Female: yes Male: yes | 115 | Phase 3 | France;Canada;Belgium;Germany;United Kingdom;Japan | |||
| 14 | NCT02020889 | February 5, 2014 | 12 February 2018 | A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis | A Double-blind, Randomised, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis in Subjects Receiving Standard of Care Therapy | Churg-Strauss Syndrome | Biological: Mepolizumab;Drug: Placebo | GlaxoSmithKline | National Institute of Allergy and Infectious Diseases (NIAID) | Not recruiting | 18 Years | N/A | All | 136 | Phase 3 | United States;Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom |
| 15 | EUCTR2012-004385-17-BE | 22/11/2013 | 30 April 2018 | Study of mepolizumab versus placebo in addition to standard of care for the treatment of Eosinophilic Granulomatosis with Polyangiitis. | A Double-blind, Randomised, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard of Care Therapy. | Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard of Care Therapy. MedDRA version: 17.1 Level: LLT Classification code 10018701 Term: Granulomatous disease System Organ Class: 100000004867 MedDRA version: 17.1 Level: LLT Classification code 10014956 Term: Eosinophilic granuloma System Organ Class: 100000004864 MedDRA version: 17.1 Level: LLT Classification code 10072580 Term: Granulomatous polyangiitis System Organ Class: 100000004866 MedDRA version: 17.1 Level: LLT Classification code 10014957 Term: Eosinophilic granulomatous vasculitis System Organ Class: 100000004870 MedDRA version: 17.1 Level: LLT Classification code 10056218 Term: Necrotising granulomatous vasculitis System Organ Class: 100000004866 MedDRA version: 17.1 Level: LLT Classification code 10068462 Term: Eosinophilic asthma System Organ Class: 100000004855 MedDRA version: 17.1 Level: LLT Classification code 10036023 Term: Polyangiitis System Organ Class: 100000004866 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Mepolizumab Product Code: SB-240563 Pharmaceutical Form: Injection INN or Proposed INN: Mepolizumab CAS Number: 196078-29-2 Current Sponsor code: SB-240563 Other descriptive name: Recombinant humanized monoclonal antibody specific for human IL-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Injection Route of administration of the placebo: Subcutaneous use | GlaxoSmithKline Research & Development Ltd | Not Recruiting | Female: yes Male: yes | 130 | Phase 3 | France;United States;Canada;Spain;Belgium;Germany;Japan;Italy;United Kingdom | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | NCT00751517 | September 2008 | 19 February 2015 | Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides | Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides. A Randomized Controlled Trial. | Wegener's Granulomatosis;Churg-Strauss Syndrome;Microscopic Polyangiitis;Polyarteritis Nodosa | Drug: Methotrexate;Drug: Cyclophosphamide | University of Parma | Not recruiting | 18 Years | 80 Years | Both | Phase 2 | Italy | ||
| 17 | EUCTR2006-001791-20-DE | 30/06/2008 | 19 March 2012 | A Phase II, single center open label, prospective trial to evaluate the efficacy and safety of mepolizumab for patients with refractory or relapsing Churg Strauss Syndrome - MEPOCHUSS | A Phase II, single center open label, prospective trial to evaluate the efficacy and safety of mepolizumab for patients with refractory or relapsing Churg Strauss Syndrome - MEPOCHUSS | Churg-Strauss-Syndrome MedDRA version: 9.1 Level: LLT Classification code 10009164 Term: Churg Strauss syndrome | Product Name: Mepolizumab Product Code: SB-240563 Pharmaceutical Form: Powder for solution for injection CAS Number: 196078-29-2 Current Sponsor code: SB-240563 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250- | University Hospital of Schleswig-Holstein (UKSH), Campus Lübeck | Authorised | Female: yes Male: yes | Phase 2 | Germany | ||||
| 18 | NCT00647166 | May 2008 | 19 October 2015 | Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) | Evaluation of a New Treatment Strategy for Patients With Microscopic Polyangiitis, Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) Without Poor Prognosis Factors | MPA;PAN or EGPA With FFS=0;At Diagnosis or Within the First 15 Days Following Initiation of Corticosteroids | Drug: corticosteroid and azathioprine;Drug: corticosteroid and placebo | Assistance Publique - Hôpitaux de Paris | Not recruiting | 18 Years | N/A | Both | 114 | Phase 3 | France | |
| 19 | NCT00527566 | September 2007 | 16 December 2017 | Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome | Mepolizumab As a Steroid Sparing Treatment Option in the Churg Strauss Syndrome | Churg Strauss Syndrome | Biological: Mepolizumab | Brigham and Women's Hospital | GlaxoSmithKline | Not recruiting | 19 Years | N/A | All | 10 | Phase 1/Phase 2 | United States |
| 20 | NCT00424749 | June 2007 | 19 October 2017 | Rituxan in Churg Strauss Syndrome With Renal Involvement | A Pilot Study on the Use of Rituximab in the Treatment of Churg- Strauss Syndrome With Renal Involvement | Churg-Strauss Syndrome | Drug: Rituximab;Drug: Prednisone | Fernando Fervenza | Genentech, Inc.;Biogen;National Center for Research Resources (NCRR) | Not recruiting | 18 Years | N/A | All | 4 | Phase 2 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | JPRN-JapicCTI-060242 | 01/2/2006 | 2 April 2019 | Phase 3 study of GGS in patients with CSS/AGA | Double-blind, Randomized clinical study of GGS (Intravenous Immunoglobulin) in patients with CSS/AGA. Phase 3 study. | Churg-Strauss Syndrome (CSS) / Allergic Granulomatous Angiitis (AGA) | Intervention name : Freeze-Dried Sulfonated Human Normal Immunoglobulin (GGS) Dosage And administration of the intervention : Intravenous drip infusion Control intervention name : Placebo (physiological saline) Dosage And administration of the control intervention : Intravenous drip infusion | TEIJIN PHARMA LIMITED | 20 | 74 | BOTH | 21 | Phase 3 | |||
| 22 | NCT00307671 | July 2005 | 19 February 2015 | Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years | Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Comparison of Two Strategies Combining Steroids With or Without Immunosuppressants | Vasculitis;Wegener's Granulomatosis;Microscopic Polyangiitis;Churg-Strauss Syndrome;Polyarteritis Nodosa | Drug: prednisone, methylprednisolone,cyclophosphamides;Drug: Cyclophosphamide, Azathioprine,prednisone,methylprednisolone;Drug: Mycophenolate mofetil,methotrexate | Assistance Publique - Hôpitaux de Paris | Not recruiting | 65 Years | N/A | Both | 108 | Phase 4 | France | |
| 23 | NCT00307593 | May 2004 | 19 February 2015 | RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides | Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides With Positive ANCA After Relapse or Resistant Immunosuppressant Therapies | Wegener's Granulomatosis;Churg-Strauss Syndrome;Microscopic Polyangiitis | Drug: Infliximab;Drug: Rituximab | Assistance Publique - Hôpitaux de Paris | Not recruiting | 18 Years | N/A | Both | 20 | N/A | France | |
| 24 | NCT00266565 | December 2001 | 16 December 2017 | Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome | A Phase I/II Study of the Effect of Intravenous Anti-IL-5 (Mepolizumab) SB 240563 on the Outcome and Management of Hypereosinophilic Syndromes | Hypereosinophilic Syndromes;Eosinophilic Gastroenteritis;Churg-Strauss Syndrome;Eosinophilic Esophagitis | Drug: Mepolizumab | Children's Hospital Medical Center, Cincinnati | Not recruiting | 18 Years | 65 Years | All | 24 | Phase 1/Phase 2 | United States | |
| 25 | NCT00006055 | March 2000 | 19 February 2015 | Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases | Purpura, Schoenlein-Henoch;Graft Versus Host Disease;Anemia, Hemolytic, Autoimmune;Rheumatoid Arthritis;Churg-Strauss Syndrome;Hypersensitivity Vasculitis;Wegener's Granulomatosis;Systemic Lupus Erythematosus;Giant Cell Arteritis;Pure Red Cell Aplasia;Juvenile Rheumatoid Arthritis;Polyarteritis Nodosa;Autoimmune Thrombocytopenic Purpura;Takayasu Arteritis | Drug: anti-thymocyte globulin;Drug: cyclophosphamide;Drug: cyclosporine;Drug: filgrastim;Drug: methylprednisolone;Drug: prednisone;Procedure: Autologous Peripheral Blood Stem Cell Transplantation | Fairview University Medical Center | Not recruiting | 1 Year | 55 Years | Both | 10 | N/A | United States | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 26 | NCT00399399 | July 1996 | 19 February 2015 | CHUSPAN SCS BP Treatment of Churg–Strauss Syndrome Without Poor-Prognosis Factors | CHUSPAN SCS BP Treatment of Churg–Strauss Syndrome Without Poor-Prognosis Factors: a Prospective Randomized Study in 72 Patients. | Churg-Strauss Syndrome | Drug: azathioprine;Drug: cyclophosphamide | Hospices Civils de Lyon | Not recruiting | 15 Years | 90 Years | Both | 72 | Phase 4 | Switzerland |